AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Short Interest Up 429.9% in January

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the recipient of a large growth in short interest in January. As of January 30th, there was short interest totaling 328,268 shares, a growth of 429.9% from the January 15th total of 61,954 shares. Based on an average daily volume of 114,674 shares, the days-to-cover ratio is presently 2.9 days. Currently, 10.0% of the shares of the stock are sold short. Currently, 10.0% of the shares of the stock are sold short. Based on an average daily volume of 114,674 shares, the days-to-cover ratio is presently 2.9 days.

AIM ImmunoTech Price Performance

Shares of AIM stock opened at $0.98 on Wednesday. The company has a market capitalization of $3.20 million, a price-to-earnings ratio of -0.05 and a beta of 1.26. AIM ImmunoTech has a one year low of $0.77 and a one year high of $36.00. The company’s fifty day moving average price is $1.27 and its 200-day moving average price is $2.01.

AIM ImmunoTech (NYSEAMERICAN:AIM) last issued its earnings results on Monday, November 17th. The company reported ($1.57) earnings per share for the quarter. The company had revenue of $0.03 million for the quarter. Equities research analysts expect that AIM ImmunoTech will post -0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Zacks Research downgraded AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Sabby Management LLC purchased a new position in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 28,855 shares of the company’s stock, valued at approximately $79,000. AIM ImmunoTech accounts for approximately 0.1% of Sabby Management LLC’s investment portfolio, making the stock its 22nd biggest holding. Sabby Management LLC owned approximately 1.06% of AIM ImmunoTech as of its most recent SEC filing. 12.02% of the stock is owned by institutional investors and hedge funds.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.